Compare Beyond Meat Inc (BYND) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Novavax Inc — how do they compare? Beyond Meat Inc trades at $0.64 (market cap $320.23M), while Novavax Inc trades at $8.3 (market cap $1.38B). The key difference: Novavax Inc is far larger — about 4.3× Beyond Meat Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| BYND | NVAX | |
|---|---|---|
Market Cap | $320.23M | $1.38B |
Sector | Consumer Staples | Health |
52-Week High | $4.28 | $11.19 |
52-Week Low | $0.52 | $6.22 |
Enterprise Value | $630.23M | $889.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYND trades at $0.63, down 4.15% today, reflecting persistent bearish sentiment amid declining revenues and negative cash flow from operations. The stock shows technical weakness with moving averages signaling bearish momentum, though oversold RSI conditions suggest potential for near-term bounce. Recent earnings show mixed results with Q1 2026 beating expectations but Q4 2025 and Q3 2025 missing estimates. The company continues expansion efforts with new product launches including Beyond Steak Filet and protein beverages.
Investment outlook remains challenging with 57% analyst sell ratings and negative operating cash flow of $145M in 2025. While valuation metrics appear attractive with P/S of 0.65 and EV/EBITDA of 2.08, ongoing revenue declines and reliance on financing activities for liquidity pose significant risks. The turnaround strategy through product diversification faces execution challenges in a competitive plant-based protein market.
Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.
The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
